公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2015 | Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: Pharmacokinetics and recommended phase 2 dose | Venkatakrishnan K.; Kim T.M.; CHIA-CHI LIN ; Thye L.S.; Chng W.J.; Ma B.; Chen M.H.; Zhou X.; Liu H.; Kelly V.; Kim W.S. | Investigational New Drugs | 26 | 27 | |
2019 | Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network | Soekojo C.Y.; Kim K.; SHANG-YI HUANG ; Chim C.-S.; Takezako N.; Asaoku H.; Kimura H.; Kosugi H.; Sakamoto J.; Gopalakrishnan S.K.; Nagarajan C.; Wei Y.; Moorakonda R.; Lee S.L.; Lee J.J.; Yoon S.-S.; Kim J.S.; Min C.K.; Lee J.-H.; Durie B.; Chng W.J. | Blood Cancer Journal | 12 | 7 | |
2018 | Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop | Tan D.; Lee J.H.; Chen W.; Shimizu K.; Hou J.; Suzuki K.; Nawarawong W.; SHANG-YI HUANG ; Sang Chim C.; Kim K.; Kumar L.; Malhotra P.; Chng W.J.; Durie B.; for the Asian Myeloma Network | Leukemia and Lymphoma | 16 | 13 |